Aravive (ARAV) News Today $0.04 0.00 (0.00%) (As of 09/27/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of LegalApril 23, 2024 | finance.yahoo.comDiabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsightApril 2, 2024 | finance.yahoo.comTelo Genomics Engages US Diagnostics Experts to Power Product Adoption in the USJanuary 30, 2024 | finance.yahoo.comCrude Oil Rises Over 1%; Processa Pharmaceuticals Shares SlideJanuary 18, 2024 | msn.comWhy Is Nuvve (NVVE) Stock Down 31% Today?January 18, 2024 | msn.comWhy Is Aravive (ARAV) Stock Down 52% Today?January 18, 2024 | markets.businessinsider.comAravive Shares Drop 53%, Company to Delist and Deregister StockJanuary 17, 2024 | marketwatch.comAravive, Inc. to Delist from The Nasdaq Stock MarketJanuary 17, 2024 | finance.yahoo.comTrading was temporarily halted for "ARAV" at 04:01 PM with a stated reason of "News pending."January 17, 2024 | marketbeat.comAravive Stock (NASDAQ:ARAV), Short Interest ReportDecember 27, 2023 | benzinga.comAravive Stock (NASDAQ:ARAV) Dividends: History, Yield and DatesDecember 27, 2023 | benzinga.comHouston is building it. Why won't they come?December 8, 2023 | bizjournals.comHouston companies, universities win nearly $50.7 million in latest CPRIT awardsNovember 20, 2023 | bizjournals.comAravive Inc ARAVNovember 12, 2023 | morningstar.comAravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?October 13, 2023 | finance.yahoo.comAravive, Inc. (ARAV) Stock Historical Prices & Data - Yahoo FinanceSeptember 24, 2023 | finance.yahoo.comThinking about buying stock in Limbach Holdings, Aravive, Up Fintech Holding, YS Biopharma, or Big Lots?August 29, 2023 | benzinga.comCantor Fitzgerald Downgrades AraviveAugust 23, 2023 | 247wallst.comCantor Fitzgerald Downgrades Aravive (ARAV)August 22, 2023 | msn.comCantor cuts Aravive to neutral as biotech struggles to stay in businessAugust 22, 2023 | msn.comAnalyst Downgrades Aravive: Grapples With Trial Setback, Strategic AlternativesAugust 22, 2023 | markets.businessinsider.comWilliam Blair Downgrades Aravive (ARAV)August 4, 2023 | msn.comAravive (ARAV) Price Target Decreased by 5.77% to 12.50August 3, 2023 | msn.comAravive sinks as Phase 3 ovarian cancer trial for lead asset failsAugust 3, 2023 | seekingalpha.comAravive Shares Hit 52-Week Low After Trial Misses Primary EndpointAugust 3, 2023 | marketwatch.comAravive (NASDAQ:ARAV) Plummets On Phase 3 Disappointment In Ovarian CancerAugust 3, 2023 | msn.comH.C. Wainwright downgrades Aravive (ARAV) to a HoldAugust 3, 2023 | markets.businessinsider.comWhy Is Aravive Stock Sinking Today?August 3, 2023 | msn.comAravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian CancerAugust 3, 2023 | finance.yahoo.comWhy Is Aravive (ARAV) Stock Down 58% Today?August 3, 2023 | investorplace.comTrading was temporarily halted for "ARAV" at 04:08 PM with a stated reason of "News pending."August 2, 2023 | marketbeat.comAravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023July 28, 2023 | finance.yahoo.comAravive (NASDAQ:ARAV) Rating Reiterated by Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $18.00 price target on shares of Aravive in a research note on Friday.July 21, 2023 | marketbeat.comAravive, Inc.'s (NASDAQ:ARAV) largest shareholders are private equity firms with 50% ownership, individual investors own 22%July 19, 2023 | finance.yahoo.comAravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023July 14, 2023 | finance.yahoo.comCantor Fitzgerald Reiterates Overweight on Aravive, Maintains $18 Price TargetJuly 3, 2023 | benzinga.comThe Latest Analyst Ratings for AraviveJuly 3, 2023 | markets.businessinsider.comPediatric Growth Hormone Deficiency Market expected to rise | Companies – Ascendis Pharma, OPKO Health, Aravive, expected to drive marketJuly 3, 2023 | benzinga.comARAV Jul 2023 7.500 callJune 20, 2023 | finance.yahoo.comAravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)June 13, 2023 | finance.yahoo.comAravive To Participate in the Jefferies Global Healthcare ConferenceJune 5, 2023 | finance.yahoo.comEF Hutton Keeps Their Buy Rating on Aravive (ARAV)June 5, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Aravive (ARAV)June 5, 2023 | markets.businessinsider.comAravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023May 25, 2023 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Sonnet BioTherapeutics Holdings (SONN), Aravive (ARAV) and Cyclacel Pharmaceuticals (CYCC)May 25, 2023 | markets.businessinsider.comAnalyst Expectations for Aravive's FutureMay 25, 2023 | msn.comAravive: Very Small Company With Late Stage Trial In Ovarian CancerMay 24, 2023 | msn.com7 Short-Interest Stocks to Target for Explosive GainsMay 18, 2023 | markets.businessinsider.comCantor Fitzgerald Reiterates Aravive (ARAV) Overweight RecommendationMay 18, 2023 | msn.comAravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell CarcinomaMay 16, 2023 | finance.yahoo.com Get Aravive News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address Massive NVIDIA Sell-Off: Are We Headed for a Market Collapse? (Ad)You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this year. But here's what's even more concerning... Click here for his urgent warning - and 4 steps you need to take today to protect your retirement to ARAV Media Mentions By Week ARAV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARAV News Sentiment▼0.000.73▲Average Medical News Sentiment ARAV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARAV Articles This Week▼00▲ARAV Articles Average Week Get Aravive News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VAXX News Today ADXN News Today AWH News Today IMNN News Today GLYC News Today PHXM News Today VCNX News Today AGRX News Today FBRX News Today CDT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARAV) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredIt’s over.We found a tiny company which provides the backbone for the entire $15.7 trillion AI industry... It's used ...Behind the Markets | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUrgent 2024 Election Summit [link enclosed]With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredWhat would a 22% dividend do for you?Let's do a little math here... To double your money at a 3% rate of return, you would need around 23 years....Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free arav Stock Alerts